#tenofovir disoproxil fumarate

Chinese researchers studied 81 women with chronic hepatitis B who began taking Viread before pregnancy.

Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.

A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.

Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.

Gilead Sciences has released multiple combo tablets that contain the updated tenofovir, which is linked to improved bone and kidney makers.

Nevertheless, researchers advise careful kidney monitoring when pairing the medications.

A recent study analyzed kidney parameters among those with HIV who were treated for hep C with the regimen.

The once-daily regimen includes the integrase inhibitor bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).

Largest-ever analysis of bone loss in the HIV population found that treating hep C, taking vitamin D and exercising might be preventive.

Regardless of whether individuals have hepatitis B or C, the improvement tends to occur quickly.

A 96-week study also found that switching from Viread to Vemlidy led to improvements in liver enzyme levels.

Two cases suggest that Viread alone may not be enough to prevent HIV through pre-exposure prophylaxis (PrEP)

An updated version of Viread, called TAF, combats hepatitis B as effectively as the older drug and is safer for bone and kidney health.

Merck’s investigational hepatitis C treatment grazoprevir/elbasvir cured high rates of the virus among individuals coinfected with HIV.

Two and a half years into a PrEP program in San Francisco, none of the more than 600 gay men taking Truvada have contracted the HIV.

Since curing HCV, Gilead has more than doubled its annual drug sales, leaving the company with $8.61 billion for further investments.